Developer docs
API playgroundTry for free, no card

Search company profiles

Qubit Pharmaceuticals

Full company profile

uuid0000olz

Namestring
Qubit Pharmaceuticals
Legal namestring
QUBIT PHARMACEUTICALS
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Qubit Pharmaceuticals is a Paris-headquartered Deep Tech company, founded in 2020, that applies quantum computing, physics-based simulation and artificial intelligence to accelerate drug discovery for targets previously considered undruggable. Its proprietary ATLAS platform combines 50+ PetaFLOPS of NVIDIA DGX AI compute, 1000+ nanoseconds per day of polarizable molecular dynamics simulation, and hybrid HPC–quantum computing readiness over 30 qubits to deliver high-precision molecular modeling and molecule generation. In May 2025 the company extended this stack with FeNNix-Bio1, a quantum-enabled foundation model for biomolecular systems co-developed with Sorbonne University that is positioned as the first AI model capable of simulating chemical reactivity at quantum-level accuracy and scale.

The company operates a B2B partnership-based business model, monetising through joint drug discovery programs, in-licensing/out-licensing opportunities, and co-development deals that combine professional services with potential milestone payments and royalties. Customer segments are pharmaceutical and biotechnology companies seeking pipeline acceleration, alongside academic and research institutions used for technology co-development and biological validation (e.g., Institut Curie for TREX1 cancer immunotherapy, University of Bordeaux, Centre for Quantum Technologies Singapore, Argonne National Laboratory). Go-to-market is direct enterprise engagement; pricing is bespoke and not publicly disclosed.

Qubit runs an internal and partnered pipeline of six drug discovery programs — targeting KAT6A, RAS/RAF, TREX1 (STING pathway), IL4R, USP7 and MRas — plus 16 additional discovery programs in oncology, inflammation and antivirals, including an RNA therapeutics platform. The team of 60+ employees includes 30+ PhDs across offices in Paris, Boston and Chicago, and is led by five co-founders heading quantum chemistry laboratories at Sorbonne University, Washington University in St. Louis and the University of Texas at Austin. The company has raised $25M+ from Xange, Omnes, Quantonation, Octave Klaba and the European Innovation Council, and was named a World Economic Forum Technology Pioneer in 2024.

Short descriptiontext

Qubit Pharmaceuticals is a Paris-based Deep Tech company building quantum-AI molecular modeling tools, including the ATLAS platform and FeNNix-Bio1 foundation model, to accelerate drug discovery. It partners with pharmaceutical companies, biotechs and academic institutions on co-developed drug programs in oncology, inflammation and antivirals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
computational drug discovery, quantum molecular modeling, pharmaceutical research services, molecular dynamics simulation, AI drug design
Industry4 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAGAEAB
Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand)
Hardware, Technology & Telecom/Quantum Computing/Quantum Simulation & Digital Twins
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Laboratory Analytical Instruments3826
Product category
Computational Drug Discovery Software
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Joint Drug Discovery Programs
TypeProfessional Services
Description

Co-development partnerships with pharmaceutical and biotech companies where Qubit provides computational drug discovery services using its Atlas platform, with costs and outcomes shared between parties.

qubit-pharmaceuticals.com
2Licensing and Co-development Deals
TypeLicensing Royalties
Description

Revenue from licensing its technology platform and co-developing drug candidates with partners, with potential milestone payments and royalties on successful drug development.

qubit-pharmaceuticals.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Qubit Pharmaceuticals develops and operates ATLAS, a proprietary computational platform combining quantum computing, artificial intelligence, and physics-based molecular modeling to accelerate drug discovery. The platform enables high-precision molecular simulation, molecule generation, and lead optimization for pharmaceutical and biotech partners through joint drug discovery programs, co-development, and licensing arrangements. It also operates an internal pipeline of drug discovery programs in oncology, inflammation, antivirals, and RNA therapeutics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • Reduces drug candidate selection and optimization time by 50%
+6 more records
Product overview1 text field

Qubit Pharmaceuticals offers a unified platform architecture centered on the ATLAS platform, a proprietary quantum AI and physics-inspired system for high-precision molecular modeling in drug discovery. ATLAS is enhanced by FeNNix-Bio1, a quantum AI foundation model that extends the platform's capabilities to provide quantum-level accuracy for molecular simulations at scale. The company operates a pipeline of drug discovery programs in oncology, inflammation, and antivirals, including programs targeting KAT6A, RAS/RAF, TREX1, STING pathway, and RNA platforms. The technology stack combines high-performance computing (50+ PetaFLOPS AI), quantum computing capabilities (30+ qubits), and molecular dynamics simulation (1000+ nanoseconds per day) to enable drug discovery workflows from target characterization through lead optimization.

Product and service2 records
1ATLAS Platform
CategoryComputational Drug Discovery Platform
Description

Proprietary quantum, AI and physics-inspired computational platform for high-precision molecular modeling and drug discovery, offered to pharmaceutical and biotech partners through joint drug discovery programs, in-licensing, out-licensing, and co-development arrangements.

2FeNNix-Bio1 Quantum AI Foundation Model
CategoryAI Foundation Model
Description

Quantum AI foundation model for biomolecular simulations that delivers quantum-level accuracy at speeds rivalling traditional force field methods, enabling simulation of molecular reactivity, protein dynamics, and drug-protein interactions at unprecedented scale.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

Two-year strategic research collaboration to develop and implement novel quantum algorithms for molecular discovery. Implementing variational quantum eigensolvers, quantum phase estimation, and qMCMC algorithms on Quantinuum H2 and Helios quantum hardware. First successful implementation of qMCMC algorithm on physical quantum hardware.

2Sorbonne University
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-20
Description

Joint development of FeNNix-Bio1 quantum AI model for drug discovery. Partnership leverages unprecedented computing power from GENCI, EuroHPC and Argonne National Laboratory to create world's most accurate synthetic molecular database.

3Argonne National Laboratory
Strategic tierMajorTypeTechnology or IntegrationAnnounced on2024-11-29
Description

Awarded 1.44 million GPU hours through INCITE Program for access to Aurora exascale supercomputer for molecular simulation research

qubit-pharmaceuticals.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-07
Description

Joint research on analog quantum computing for drug discovery, specifically for solvent configuration prediction in protein structures. Demonstrated algorithm with 14 qubits in practical drug design context.

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-09-26
Description

Joint winner of Wellcome Trust's Quantum for Bio program alongside Pasqal for quantum computing applications in biology

Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2023-06-12
Description

Joined consortium to innovate in drug design using quantum computing resources in Quebec

7Université de Sherbrooke
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-03-31
Description

Partnership with Institute of Pharmacology at University of Sherbrooke, Canada for drug discovery research

qubit-pharmaceuticals.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-30
Description

Collaboration to develop drug candidates targeting TREX1 enzyme for cancer immunotherapy. Qubit provides computational modeling via Atlas platform, Institut Curie provides biological validation through their Cancer Immunotherapy Center.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2023-01-30
Description

Research partnership for biochemical and structural characterization of identified drug leads in cancer therapy development. Working with CNRS researchers specialized in molecular interactions.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Schrödinger is the publicly listed leader in physics-based computational drug discovery, offering platforms (LiveDesign, Maestro) for molecular simulation and FEP+ for binding free energy. Directly comparable to Qubit's ATLAS platform; notably, Qubit's new CTO Robin Chaudret was previously an Executive Director at Schrödinger.

TypeDirect peer
Description

XtalPi combines AI, quantum physics, and large-scale HPC for small-molecule drug discovery and has raised over $700M. It is the most direct peer to Qubit, with a near-identical quantum-plus-AI positioning and pharma partnership model.

TypeDirect peer
Description

Recursion is an AI-driven drug discovery company combining high-throughput biology with deep learning. Comparable as an AI-native drug discovery platform pursuing both internal pipeline and pharma partnerships; differentiated from Qubit by its wet-lab emphasis versus Qubit's in silico/quantum focus.

TypeDirect peer
Description

Insilico Medicine uses generative AI for target identification and molecule generation, with a pipeline that has reached clinical stage. Comparable to Qubit as an AI-first drug discovery company pursuing pharma partnerships and internal pipeline development.

5Isomorphic Labs
TypeDirect peer
Description

Isomorphic Labs is Alphabet's drug discovery spin-out leveraging DeepMind's AlphaFold technology. Directly comparable to Qubit as a foundation-model-driven drug discovery company pursuing major pharma partnerships (Novartis, Lilly).

TypeDirect peer
Description

Atomwise applies AI (AtomNet) to small-molecule drug discovery and has partnered with multiple large pharma companies. Comparable as an AI-first drug discovery platform pursuing a similar partnership-driven GTM.

7Iambic Therapeutics
TypeEmerging player
Description

Iambic (formerly Entasis) uses AI/ML for small-molecule drug discovery with a foundation-model approach (Enchant and NeuralPLexer). Comparable in early-stage AI drug discovery with similar pipeline ambition.

TypeEmerging player
Description

Polaris Quantum Biotech applies quantum computing to drug design, with a narrower focus on oncology targets. Comparable to Qubit as a quantum-focused drug discovery peer, though smaller in scale and pipeline breadth.

TypeEmerging player
Description

Menten AI develops AI-designed protein therapeutics and de novo enzymes. Comparable as an AI-first biotech platform with quantum/ML underpinnings, overlapping with Qubit's protein engineering use cases.

TypeOthers
Description

Pasqal is a neutral-atom quantum computing hardware company and an active collaborator with Qubit on analog quantum algorithms for solvent configuration. Comparable as an ecosystem enabler supplying the underlying quantum compute that powers Qubit's platform rather than as a direct drug discovery competitor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature8 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Qubit Pharmaceuticals

Computational Drug Discovery Softwarequbit-pharmaceuticals.com

Qubit Pharmaceuticals is a Paris-based Deep Tech company building quantum-AI molecular modeling tools, including the ATLAS platform and FeNNix-Bio1 foundation model, to accelerate drug discovery. It partners with pharmaceutical companies, biotechs and academic institutions on co-developed drug programs in oncology, inflammation and antivirals.

What Qubit Pharmaceuticals does

Qubit Pharmaceuticals is a Paris-headquartered Deep Tech company, founded in 2020, that applies quantum computing, physics-based simulation and artificial intelligence to accelerate drug discovery for targets previously considered undruggable. Its proprietary ATLAS platform combines 50+ PetaFLOPS of NVIDIA DGX AI compute, 1000+ nanoseconds per day of polarizable molecular dynamics simulation, and hybrid HPC–quantum computing readiness over 30 qubits to deliver high-precision molecular modeling and molecule generation. In May 2025 the company extended this stack with FeNNix-Bio1, a quantum-enabled foundation model for biomolecular systems co-developed with Sorbonne University that is positioned as the first AI model capable of simulating chemical reactivity at quantum-level accuracy and scale.

The company operates a B2B partnership-based business model, monetising through joint drug discovery programs, in-licensing/out-licensing opportunities, and co-development deals that combine professional services with potential milestone payments and royalties. Customer segments are pharmaceutical and biotechnology companies seeking pipeline acceleration, alongside academic and research institutions used for technology co-development and biological validation (e.g., Institut Curie for TREX1 cancer immunotherapy, University of Bordeaux, Centre for Quantum Technologies Singapore, Argonne National Laboratory). Go-to-market is direct enterprise engagement; pricing is bespoke and not publicly disclosed.

Qubit runs an internal and partnered pipeline of six drug discovery programs — targeting KAT6A, RAS/RAF, TREX1 (STING pathway), IL4R, USP7 and MRas — plus 16 additional discovery programs in oncology, inflammation and antivirals, including an RNA therapeutics platform. The team of 60+ employees includes 30+ PhDs across offices in Paris, Boston and Chicago, and is led by five co-founders heading quantum chemistry laboratories at Sorbonne University, Washington University in St. Louis and the University of Texas at Austin. The company has raised $25M+ from Xange, Omnes, Quantonation, Octave Klaba and the European Innovation Council, and was named a World Economic Forum Technology Pioneer in 2024.

Qubit Pharmaceuticals firmographics

Firmographics
Name
Qubit Pharmaceuticals
Legal name
QUBIT PHARMACEUTICALS
Website
https://qubit-pharmaceuticals.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
Qubit Pharmaceuticals is a Paris-based Deep Tech company building quantum-AI molecular modeling tools, including the ATLAS platform and FeNNix-Bio1 foundation model, to accelerate drug discovery. It partners with pharmaceutical companies, biotechs and academic institutions on co-developed drug programs in oncology, inflammation and antivirals.
Ownership category
akta.pro rank

Qubit Pharmaceuticals industry classification

Industry
Product category
Computational Drug Discovery Software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHDAGAEAB
Pharmaceutical & Biotech R&D Simulation (drug discovery, protein/ligand)
Hardware, Technology & Telecom/Quantum Computing/Quantum Simulation & Digital Twins
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Computational drug discovery
  • Quantum molecular modeling
  • Pharmaceutical research services
  • Molecular dynamics simulation
  • AI drug design

Where Qubit Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Offices3 records

Markets served

Qubit Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Joint Drug Discovery Programs: Co-development partnerships with pharmaceutical and biotech companies where Qubit provides computational drug discovery services using its Atlas platform, with costs and outcomes shared between parties.
  2. Licensing and Co-development Deals: Revenue from licensing its technology platform and co-developing drug candidates with partners, with potential milestone payments and royalties on successful drug development.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Qubit Pharmaceuticals product offering

Product offering

Core offering

Qubit Pharmaceuticals develops and operates ATLAS, a proprietary computational platform combining quantum computing, artificial intelligence, and physics-based molecular modeling to accelerate drug discovery. The platform enables high-precision molecular simulation, molecule generation, and lead optimization for pharmaceutical and biotech partners through joint drug discovery programs, co-development, and licensing arrangements. It also operates an internal pipeline of drug discovery programs in oncology, inflammation, antivirals, and RNA therapeutics.

Product overview

Qubit Pharmaceuticals offers a unified platform architecture centered on the ATLAS platform, a proprietary quantum AI and physics-inspired system for high-precision molecular modeling in drug discovery. ATLAS is enhanced by FeNNix-Bio1, a quantum AI foundation model that extends the platform's capabilities to provide quantum-level accuracy for molecular simulations at scale. The company operates a pipeline of drug discovery programs in oncology, inflammation, and antivirals, including programs targeting KAT6A, RAS/RAF, TREX1, STING pathway, and RNA platforms. The technology stack combines high-performance computing (50+ PetaFLOPS AI), quantum computing capabilities (30+ qubits), and molecular dynamics simulation (1000+ nanoseconds per day) to enable drug discovery workflows from target characterization through lead optimization.

Differentiator

Problem solved

Functional benefit

Products and services

  • ATLAS Platform Proprietary quantum, AI and physics-inspired computational platform for high-precision molecular modeling and drug discovery, offered to pharmaceutical and biotech partners through joint drug discovery programs, in-licensing, out-licensing, and co-development arrangements.
  • FeNNix-Bio1 Quantum AI Foundation Model Quantum AI foundation model for biomolecular simulations that delivers quantum-level accuracy at speeds rivalling traditional force field methods, enabling simulation of molecular reactivity, protein dynamics, and drug-protein interactions at unprecedented scale.

Quantifiable outcome

  • Reduces drug candidate selection and optimization time by 50%
  • +6 more outcomes

Companies that use Qubit Pharmaceuticals

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Qubit Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature8 records

Qubit Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core, major and minor.

  • Centre for Quantum Technologies (CQT)coreStrategic or Co-development Partner · 30 April 2026Two-year strategic research collaboration to develop and implement novel quantum algorithms for molecular discovery. Implementing variational quantum eigensolvers, quantum phase estimation, and qMCMC algorithms on Quantinuum H2 and Helios quantum hardware. First successful implementation of qMCMC algorithm on physical quantum hardware.
  • Sorbonne UniversitycoreStrategic or Co-development Partner · 20 May 2025Joint development of FeNNix-Bio1 quantum AI model for drug discovery. Partnership leverages unprecedented computing power from GENCI, EuroHPC and Argonne National Laboratory to create world's most accurate synthetic molecular database.
  • Argonne National LaboratorymajorTechnology or Integration · 29 November 2024Awarded 1.44 million GPU hours through INCITE Program for access to Aurora exascale supercomputer for molecular simulation research
  • PasqalcoreStrategic or Co-development Partner · 7 October 2024Joint research on analog quantum computing for drug discovery, specifically for solvent configuration prediction in protein structures. Demonstrated algorithm with 14 qubits in practical drug design context.
  • Unitary FundminorStrategic or Co-development Partner · 26 September 2023Joint winner of Wellcome Trust's Quantum for Bio program alongside Pasqal for quantum computing applications in biology
  • Acuité Québec ConsortiumminorStrategic or Co-development Partner · 12 June 2023Joined consortium to innovate in drug design using quantum computing resources in Quebec
  • Université de SherbrookemajorStrategic or Co-development Partner · 31 March 2023Partnership with Institute of Pharmacology at University of Sherbrooke, Canada for drug discovery research
  • Institut CuriecoreStrategic or Co-development Partner · 30 January 2023Collaboration to develop drug candidates targeting TREX1 enzyme for cancer immunotherapy. Qubit provides computational modeling via Atlas platform, Institut Curie provides biological validation through their Cancer Immunotherapy Center.
  • University of BordeauxmajorStrategic or Co-development Partner · 30 January 2023Research partnership for biochemical and structural characterization of identified drug leads in cancer therapy development. Working with CNRS researchers specialized in molecular interactions.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Qubit Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Schrödinger Inc. Schrödinger is the publicly listed leader in physics-based computational drug discovery, offering platforms (LiveDesign, Maestro) for molecular simulation and FEP+ for binding free energy. Directly comparable to Qubit's ATLAS platform; notably, Qubit's new CTO Robin Chaudret was previously an Executive Director at Schrödinger.
  • XtalPi: XtalPi combines AI, quantum physics, and large-scale HPC for small-molecule drug discovery and has raised over $700M. It is the most direct peer to Qubit, with a near-identical quantum-plus-AI positioning and pharma partnership model.
  • Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery company combining high-throughput biology with deep learning. Comparable as an AI-native drug discovery platform pursuing both internal pipeline and pharma partnerships; differentiated from Qubit by its wet-lab emphasis versus Qubit's in silico/quantum focus.
  • Insilico Medicine: Insilico Medicine uses generative AI for target identification and molecule generation, with a pipeline that has reached clinical stage. Comparable to Qubit as an AI-first drug discovery company pursuing pharma partnerships and internal pipeline development.
  • Isomorphic Labs: Isomorphic Labs is Alphabet's drug discovery spin-out leveraging DeepMind's AlphaFold technology. Directly comparable to Qubit as a foundation-model-driven drug discovery company pursuing major pharma partnerships (Novartis, Lilly).
  • Atomwise: Atomwise applies AI (AtomNet) to small-molecule drug discovery and has partnered with multiple large pharma companies. Comparable as an AI-first drug discovery platform pursuing a similar partnership-driven GTM.

Emerging players

  • Iambic Therapeutics: Iambic (formerly Entasis) uses AI/ML for small-molecule drug discovery with a foundation-model approach (Enchant and NeuralPLexer). Comparable in early-stage AI drug discovery with similar pipeline ambition.
  • Polaris Quantum Biotech: Polaris Quantum Biotech applies quantum computing to drug design, with a narrower focus on oncology targets. Comparable to Qubit as a quantum-focused drug discovery peer, though smaller in scale and pipeline breadth.
  • Menten AI: Menten AI develops AI-designed protein therapeutics and de novo enzymes. Comparable as an AI-first biotech platform with quantum/ML underpinnings, overlapping with Qubit's protein engineering use cases.

Others

  • Pasqal: Pasqal is a neutral-atom quantum computing hardware company and an active collaborator with Qubit on analog quantum algorithms for solvent configuration. Comparable as an ecosystem enabler supplying the underlying quantum compute that powers Qubit's platform rather than as a direct drug discovery competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Qubit Pharmaceuticals social profiles

Digital presence

Qubit Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Qubit Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles8 records

Qubit Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Qubit Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Qubit Pharmaceuticals

What does Qubit Pharmaceuticals do?

Qubit Pharmaceuticals develops and operates ATLAS, a proprietary computational platform combining quantum computing, artificial intelligence, and physics-based molecular modeling to accelerate drug discovery. The platform enables high-precision molecular simulation, molecule generation, and lead optimization for pharmaceutical and biotech partners through joint drug discovery programs, co-development, and licensing arrangements. It also operates an internal pipeline of drug discovery programs in oncology, inflammation, antivirals, and RNA therapeutics.

Is Qubit Pharmaceuticals a public or private company?

Qubit Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Qubit Pharmaceuticals founded?

Qubit Pharmaceuticals was founded in 2020. It employs 51 to 100 people.

Where is Qubit Pharmaceuticals based?

Qubit Pharmaceuticals is headquartered in Paris, France, in the Europe region.

How does Qubit Pharmaceuticals make money?

Two revenue lines are on record. Joint Drug Discovery Programs are the primary driver. The others are licensing and Co-development Deals.

Who are Qubit Pharmaceuticals's main competitors?

Direct peers on record are Schrödinger Inc., XtalPi, Recursion Pharmaceuticals, Insilico Medicine, Isomorphic Labs and Atomwise. Emerging players are Iambic Therapeutics, Polaris Quantum Biotech and Menten AI. Pasqal is listed as an others.

Does Qubit Pharmaceuticals have an API?

No public API is recorded for Qubit Pharmaceuticals.

What industry is Qubit Pharmaceuticals in?

Qubit Pharmaceuticals's product category is Computational Drug Discovery Software. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quantum ZeitgeistLayers of quantum operations compress circuit depth for chemistryResearchers from Sorbonne Université and Qubit Pharmaceuticals developed VULCAN, a quantum chemistry framework that eliminates Hamiltonian gradient measurements in VQE calculations. It generates operator pools 4-12 times smaller than Qubit-Excitation-Based methods, achieving chemical accuracy on molecules like C3H6 with 5-20% of the measurement cost of batched ADAPT-VQE. The method enables early termination via a GPU-accelerated stochastic Epstein-Nesbet correction.ThequantuminsiderBefore the QubitQubit Pharmaceuticals' ATLAS platform integrates polarizable molecular dynamics, a quantum AI model, and a 40-qubit emulator to accelerate drug discovery. The company reports 83% faster progression from target to hit and 75% cost reduction versus industry-standard infrastructure. Equinix's neutral interconnection fabric is positioned to enable future quantum hardware integration.EquinixQubit PharmaceuticalsQubit Pharmaceuticals deployed a dedicated 192-GPU cluster in a Paris Equinix data center to run quantum-level drug simulations. The company reported an 83% acceleration in target-to-hit time and a 75% reduction in research costs. It is preparing to port its software to quantum-native hardware in five years.BioWorldQubit’s Q007-302 shows promise for breast cancerQubit Pharmaceuticals developed Q007-302, a KAT6A inhibitor with enhanced selectivity over KAT6B and KAT7 and a favorable pharmacokinetic profile. The compound aims to improve the therapeutic index of KAT6A inhibitors used in breast cancer therapy, addressing on-target toxicity such as neutropenia and anemia.BioSpaceEIT Pharma Highlights New Lonafarnib Analyses at EASL Congress 2026EIT Pharma presented new analyses from its lonafarnib development program for chronic hepatitis D at EASL Congress 2026 in Barcelona. The phase 3 D-LIVR study, the largest in CHD with over 400 subjects across 21 countries, showed histological improvement and inflammation resolution. The company expects to provide additional data from the trial over the coming months.Quantum Computing ReportCQT and Qubit Pharmaceuticals Partner to Advance Quantum Drug DiscoveryThe Centre for Quantum Technologies (CQT) in Singapore and Qubit Pharmaceuticals have launched a two-year strategic research collaboration to develop quantum algorithms for molecular discovery, achieving the first-ever experimental realization of a quantum Markov Chain Monte Carlo (qMCMC) algorithm on physical quantum hardware. The milestone was accomplished using Quantinuum's trapped-ion systems via Singapore's National Quantum Computing Hub, demonstrating the feasibility of accurate sampling tasks on NISQ devices. The partners aim to integrate quantum-enhanced capabilities into pharmaceutical research workflows to improve early-stage decision-making in drug development.ThequantuminsiderQubit Pharmaceuticals to Collaborate with the Centre for Quantum Technologies in Singapore to Advance Quantum Algorithms for Drug DiscoveryQubit Pharmaceuticals and the Centre for Quantum Technologies in Singapore have launched a two-year collaboration to develop and test quantum algorithms for molecular discovery in drug development. The partnership will implement variational quantum eigensolvers, quantum phase estimation, and quantum Markov chain Monte Carlo algorithms on Quantinuum's H2 and Helios quantum hardware systems to assess whether quantum methods can deliver computational advantages over classical approaches. The team has already deployed the qMCMC algorithm on quantum hardware for the first time, with initial results presented at Quantum Industry Day in Singapore on April 23, 2026.Quantum ZeitgeistFrench Quantum Computing Companies 2026France has developed one of the world's most structured quantum ecosystems through its €1.8 billion Plan Quantique launched in 2021, supporting five hardware champions via the PROQCIMA programme targeting 128 logical qubits by 2030, along with companies across quantum networking, security, and pharmaceutical applications. Key players include Alice & Bob (€104M Series B in January 2025), PASQAL ($145M+ raised with US expansion), Quandela (delivered 12-qubit system to CEA's EuroHPC facility), and Quobly (integrated custom wafers into STMicroelectronics' 300mm production line in December 2025), all backed by Bpifrance and Quantonation. The ecosystem has achieved notable milestones including NVIDIA partnerships across multiple companies, with Bpifrance CEO warning in September 2025 that European private capital remains significantly underinvested relative to the US and China.ForbesHow Quantum-AI Convergence Will Define The Next Decade Of InnovationThis is an opinion/analysis piece arguing that the convergence of quantum computing and AI represents the next fundamental shift in technology, with the author contending that hybrid classical-quantum systems will redefine innovation over the next decade. The article cites real-world examples including HSBC's demonstrated 34% improvement in algorithmic trading predictions using IBM's Heron quantum processor, and pharmaceutical applications at St. Jude Research Hospital and Qubit Pharmaceuticals for drug discovery. The author urges business leaders to begin preparing now by building quantum literacy, identifying use cases, and experimenting with hybrid architectures to capitalize when the convergence reaches mainstream adoption.Tech.euQubit Pharmaceuticals harnesses quantum AI to crack chemistry’s greatest challengesDeeptech company Qubit Pharmaceuticals unveiled FeNNix-Bio1, a quantum AI model for drug discovery developed in partnership with Sorbonne University, claiming it can simulate molecular behavior with quantum-level accuracy at a fraction of current time and cost. The model uses unprecedented computing power from GENCI, EuroHPC, and Argonne to train on millions of molecular simulations, achieving performance that surpasses AlphaFold in modeling protein dynamics and drug-protein interactions. The company has a pipeline of seven programs in oncology and inflammation, with its most advanced program targeting breast cancer.